A team of Mayo Clinic pathologists have discovered a new tissue biomarker, DNAJB9, for fibrillary glomerulonephritis, a rare kidney disease of unknown pathogenesis and poor outlook—nearly half of all patients end up on dialysis within four...
Jeff Meeusen, Ph.D., Provides Clinical Update on Ceramides - Insights
Jeff Meeusen, Ph.D., Co-Director of Cardiovascular Laboratory Medicine in the Department of Laboratory Medicine and Pathology at Mayo Clinic in Rochester, Minnesota, provides a clinical update on ceramides.
March 2023 - Hematopathology & Laboratory Genetics and Genomics - Insights
This "Pathways" program provides a Clinical Pathology case that includes a history, potential answers, rationale, and relevant references. This case's sub-specialties are Hematopathology and Laboratory Genetics and Genomics.
Our pharmacogenomics (PGx) testing, which is used to inform medication selection and dosing, has the potential to revolutionize medication selection for individuals with treatment-resistant depression.
Infectious diseases - Insights
Mayo Clinic offers a broad selection of tests designed for rapid identification and in-depth characterization of the causative agents of infectious diseases.
A decade-long search for answers ends at Mayo Clinic: Tyler Hart - Insights
After years of misdiagnosis, Tyler Hart found answers at Mayo Clinic, discovering he had NF155-IgG4 autoimmune nodopathy instead of CIDP
Multiomics: A new model for identifying biomarkers to predict severe COVID-19 outcomes - Insights
In a groundbreaking study, Mayo Clinic investigators have developed a multiomic molecular method to predict clinical COVID-19 (SARS-CoV-2) outcomes better than traditional cytokines. Using a machine-learning-based prediction model, the team...
BioPharma Diagnostics - Insights
BioPharma Diagnostics bring Mayo Clinic quality and expertise to collaborative engagements with biopharma, diagnostic and biotech companies to support a range of services, including clinical trial development, assay development, research...
Relentless innovation - Insights
Inspired by Mayo Clinic’s history of breaking down barriers to change medicine, we are constantly reimagining what’s possible in diagnostics.
STAT testing is available on a limited basis for patients with a suspected or known inborn error of metabolism when there is an increased risk of illness or death due to metabolic decompensation or when testing will allow for emergent...